Infliximab
An anti-TNF biologic given by drip in hospital or as an injection under the skin.
Also called: remicade, flixabi, zessly, ct-p13, ifx, inflixamab, infliximib
Related words anti-tnf biosimilar therapeutic drug monitoring
An anti-TNF biologic given by drip in hospital or as an injection under the skin.
Also called: remicade, flixabi, zessly, ct-p13, ifx, inflixamab, infliximib
Related words anti-tnf biosimilar therapeutic drug monitoring
A biosimilar is a version of a biologic medicine shown to have no meaningful differences in quality, safety or effectiveness from the original brand. For example, Remicade was the first infliximab and Remsima, Inflectra, Flixabi and Zessly are biosimilars; Humira was the first adalimumab and Amgevita, Hyrimoz, Imraldi, Idacio and Yuflyma are biosimilars. NHS England says switching between them is now accepted practice. A Cochrane review found infliximab and its CT-P13 biosimilar may work similarly.
Sources
Some people's bodies make antibodies against infliximab or adalimumab, which can stop the medicine working. Crohn's & Colitis UK says your team may check the level of medicine and antibodies in your blood. The 2025 BSG guideline says these tests can help decide whether to adjust treatment or switch to a different medicine, and NHS Lothian describes checking levels after starting and then at least yearly. Taking an immunomodulator alongside can lower the chance of antibodies.
Sources
The SONIC trial found that people who had not had these drugs before did better on infliximab plus azathioprine together than on either alone: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone. The European and UK guidelines draw on trials like this. Your team will discuss the extra monitoring and side effects of using two medicines.
Sources
Crohn's & Colitis UK explains that biologics are antibody medicines made by living cells in a lab. Each one targets a specific part of the immune system involved in inflammation: anti-TNFs (infliximab, adalimumab), the anti-integrin vedolizumab, and interleukin blockers (ustekinumab, risankizumab, mirikizumab, guselkumab). They are given by drip or by injection under the skin. Upadacitinib is a 'targeted' tablet, not a biologic.
Sources
The 2025 BSG guideline recommends starting infliximab or adalimumab together with a thiopurine to reduce the chance of the body making antibodies against the biologic. Cochrane reviews found infliximab plus azathioprine or mercaptopurine probably works better than a thiopurine alone. Crohn's & Colitis UK also explains that methotrexate can reduce these antibodies.
Sources
A Cochrane review finding infliximab combined with azathioprine or mercaptopurine probably works better than either thiopurine alone for bringing Crohn's into remission. Infliximab may work similarly to its CT-P13 biosimilar.
Topics Biologics and newer medicines Research
Jargon explained combination therapy purine analogue biosimilar CT-P13
NICE guidance on laboratory test kits that measure how much infliximab or adalimumab is in the blood and whether the body has made antibodies against the drug. The guidance was first published as diagnostics guidance 22 and has been moved into NICE's HealthTech programme without changing its content.
Topics Monitoring Biologics and newer medicines
Jargon explained therapeutic drug monitoring drug level anti-drug antibodies ELISA anti-TNF
A guide to infliximab, an anti-TNF biologic given by drip or as an injection under the skin. It lists the original brand Remicade and biosimilars such as Remsima, Inflectra, Flixabi and Zessly, and explains checks before starting, that your team may measure drug and antibody levels in your blood, and possible side effects.
Topics Biologics and newer medicines Monitoring
Jargon explained anti-TNF infusion subcutaneous biosimilar drug levels antibodies
NHS Lothian's IBD page on monitoring medicines. It explains that people on infliximab or adalimumab have their drug level checked some weeks after starting and then at least yearly, with anti-drug antibodies tested if the level is low.
Topics Monitoring Biologics and newer medicines
Jargon explained drug level anti-drug antibodies anti-TNF shared care
NICE's appraisal approving infliximab and adalimumab on the NHS for adults with severe active Crohn's disease when standard treatments such as steroids or immunosuppressants have not worked or cannot be used. It applies to biosimilar versions too, and says treatment should be reviewed at least every 12 months to decide whether to continue.
Topics Biologics and newer medicines Medicines
Jargon explained anti-TNF biosimilar conventional therapy severe active Crohn's disease
A readable summary of what the 2025 BSG guideline says about Crohn's. Key points: early 'top-down' infliximab with an immunomodulator for moderate to severe disease; avoiding long or repeated steroid courses; no longer suggesting immunomodulators alone; upadacitinib and risankizumab added; vedolizumab no longer routinely suggested; drug-level testing for anti-TNFs; early surgery as an option for limited ileocaecal disease; and offering early treatment after resection.
Topics Medicines Surgery Monitoring
Jargon explained top-down step-up therapeutic drug monitoring ileocaecal resection Rutgeerts score immunogenicity
The key trial of infliximab in 112 children with moderate to severe Crohn's. After the first three doses, 88% had improved and 59% were in remission. Children given the drug every 8 weeks afterwards did better at one year than those given it every 12 weeks. It led to infliximab being used for children.
Topics Children and young people Biologics and newer medicines
Jargon explained induction maintenance clinical response PCDAI
This trial asked whether people who improve after a first dose of infliximab should keep having it. Those given regular doses every 8 weeks were more likely to be in remission at 30 and 54 weeks, more likely to come off steroids, and stayed well for longer than those who stopped. Serious infections were no more common. It set the pattern of regular, ongoing infliximab treatment.
Topics Biologics and newer medicines Research
Jargon explained maintenance therapy remission placebo
A landmark trial of 508 adults with moderate to severe Crohn's who had never had immunosuppressants or biologics. Infliximab and azathioprine together worked best: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone and 30% on azathioprine alone. This is why many people starting infliximab are offered a second 'helper' drug alongside it.
Topics Biologics and newer medicines Immunosuppressants Research
Jargon explained combination therapy steroid-free remission mucosal healing randomised controlled trial
Explains the basics behind IBD medicines: active and inactive ingredients, brand and generic names, and what biosimilars are. It uses infliximab as an example, explaining that biosimilars meet strict standards and you may sometimes be moved to a different one.
Topics Medicines Biologics and newer medicines
Jargon explained biosimilar originator generic
A trial in people with Crohn's fistulas (abnormal tunnels, often around the anus) who had responded to infliximab. Carrying on with infliximab every 8 weeks kept people well for much longer than switching to a dummy drug. At one year, 36% on infliximab had no draining fistulas, against 19% on placebo.
Topics Around the bottom (perianal) Biologics and newer medicines
Jargon explained fistula fistulizing disease placebo
NICE's appraisal allowing mirikizumab (Omvoh) to be used for adults with moderate to severe Crohn's disease after a previous biologic has not worked or was not tolerated, or when anti-TNF medicines are unsuitable.
Topics Biologics and newer medicines Medicines
Jargon explained IL-23 inhibitor TNF-alpha inhibitor